Skip to main content
SpringerLink
Log in

Ruxolitinib

Infectious complications: 7 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Patient demographic details were obtained following personal communication with the author.

Reference

  • Polverelli N, et al. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology 36: 561-569, No. 3, Aug 2018. Available from: URL: https://doi.org/10.1002/hon.2509 - Italy

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruxolitinib. Reactions Weekly 1719, 209 (2018). https://doi.org/10.1007/s40278-018-51763-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51763-2

Search

Navigation